Free Trial

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$7.94 -0.13 (-1.61%)
As of 03:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$7.50
$8.20
50-Day Range
$0.23
$17.15
52-Week Range
$3.08
$597.60
Volume
20,764 shs
Average Volume
725,209 shs
Market Capitalization
$17.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

CYCC MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 23% of companies evaluated by MarketBeat, and ranked 855th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cyclacel Pharmaceuticals has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cyclacel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.39% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 17.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cyclacel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.39% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 17.95%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,430.00 in company stock.

  • Percentage Held by Insiders

    51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYCC Stock News Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $90.24 on January 1st, 2025. Since then, CYCC stock has decreased by 91.1% and is now trading at $8.01.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($72.00) by $71.02.

Cyclacel Pharmaceuticals's stock reverse split on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2025
Today
8/28/2025
Next Earnings (Estimated)
11/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCC
CIK
1130166
Employees
14
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($839.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Net Margins
N/A
Pretax Margin
-54,220.00%
Return on Equity
-723.64%
Return on Assets
-145.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.77
Quick Ratio
5.77

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
445.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.62 per share
Price / Book
4.91

Miscellaneous

Outstanding Shares
2,240,000
Free Float
1,093,000
Market Cap
$17.82 million
Optionable
Optionable
Beta
0.08

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners